【ChiCTR2100050580】Early detection and surveillance of COVID-19 infection by non-invasive ophthalmic evaluations
ChiCTR2100050580
正在进行
/
/
/
2021-08-29
/
/
新型冠状病毒肺炎(COVID-19)
Early detection and surveillance of COVID-19 infection by non-invasive ophthalmic evaluations
Early detection and surveillance of COVID-19 infection by non-invasive ophthalmic evaluations
1. To compare among groups on - viral load in ocular versus upper respiratory samples; - recent-onset ocular versus respiratory symptoms - COVID19-associated ocular changes 2. To follow-up on subjects with any positive ocular finding(s) up to 12 months
连续入组
其它
N/A
N/A
Food and Health Bureau - Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19)
/
2080
/
2021-09-01
2023-08-09
/
1. Confirmed cases fulfilling laboratory criteria; 2. Probable cases: epidemiological link to a confirmed case/outbreak of COVID-19 and radiological evidence of pneumonia regardless of COVID-19 testing results; 3. Convalescent cases; 4. Subjects with epidemiological link to COVID-19, who meet the CHP reporting criteria of COVID-19, inbound travellers under compulsory quarantine at designated places.；
请登录查看1. Mentally not fit for consent; 2. Patients with recent (< 6 months) pneumonia or COVID19 cannot be recruited as healthy control.；
请登录查看Food and Health Bureau - Health and Medical Research Fund
/
Food and Health Bureau - Health and Medical Research Fund的其他临床试验
香港中文大學眼科與視覺科學系的其他临床试验
- 瞼板腺功能障礙的代謝組學研究
- 復發性眼部單純疱疹病毒疾病患者的生活質素與病人自述結果：一項前瞻性橫斷面研究
- 針對甲狀腺眼疾複視療法之眼部放射治療、西羅莫司、全身性類固醇: 多中心、隨機、雙盲、假對照和安慰劑對照的臨床試驗
- 測試 CPP-抗 VEGF 治療新生血管性老年黃斑病變的安全性和有效性 第一期隨機對照臨床試驗
- 使用非玻璃體切除視網膜下注射抗血管內皮生長因子治療新生血管性老年黃斑部病變的安全性及成本效益臨床研究
- Mapping the Thyroid Associated Orbitopathy (TAO) Genes by Whole Genome Sequencing (WGS)
- Early detection and surveillance of COVID-19 infection by non-invasive ophthalmic evaluations
- A randomised controlled trial for investigation of the safety and efficacy of treating diabetic macular edema using Noctura 400 sleep mask
最新临床资讯
-
Nat Rev Clin Oncol｜AI赋能肿瘤临床试验：从流程优化到证据生成的全景透视
智药邦2026-08-12
-
康臣药业1类新药糖肾方“芪箭颗粒”获NMPA临床研究许可
康臣药业2026-08-12
-
璎黎药业2026-08-12
-
幂方健康基金2026-08-12
-
细胞与基因治疗领域2026-08-12
-
云南白药2026-08-12
-
细胞治疗前沿2026-08-12
-
广州达博生物制品有限公司2026-08-12
-
医药笔记2026-08-12
-
医药笔记2026-08-12
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 27
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 38
-
摩熵咨询 34 18
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29